AARTIPHARM

Aarti Pharmalabs Share Price

₹570.95 -0.25 (-0.04%)

21 Dec, 2024 18:09

SIP TrendupStart SIP in AARTIPHARM

Start SIP

Performance

  • Low
  • ₹566
  • High
  • ₹583
  • 52 Week Low
  • ₹400
  • 52 Week High
  • ₹722
  • Open Price₹568
  • Previous Close₹571
  • Volume277,645

Investment Returns

  • Over 1 Month -10.11%
  • Over 3 Month -10%
  • Over 6 Month -9.29%
  • Over 1 Year + 19.53%
SIP Lightning

Smart Investing Starts Here Start SIP with Aarti Pharmalabs for Steady Growth!

Invest Now

Aarti Pharmalabs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 22.7
  • PEG Ratio
  • -1
  • Market Cap Cr
  • 5,174
  • P/B Ratio
  • 2.9
  • Average True Range
  • 23.19
  • EPS
  • 25.17
  • Dividend Yield
  • 0.5
  • MACD Signal
  • -10.07
  • RSI
  • 34.49
  • MFI
  • 33.06

Aarti Pharmalabs Financials

Aarti Pharmalabs Technicals

EMA & SMA

Current Price
₹570.95
-0.25 (-0.04%)
pointer
  • stock-down_img
  • Bullish Moving Average 0
  • stock-up_img
  • Bearish Moving Average 16
  • 20 Day
  • ₹608.16
  • 50 Day
  • ₹622.03
  • 100 Day
  • ₹618.96
  • 200 Day
  • ₹587.35

Resistance and Support

573 Pivot Speed
  • R3 597.40
  • R2 589.95
  • R1 580.45
  • S1 563.50
  • S2 556.05
  • S3 546.55

What's your outlook on Aarti Pharmalabs?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Aarti Pharmalabs Ltd. is a leading pharmaceutical company in India, specializing in the manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. It caters to global markets, providing high-quality and innovative solutions for various therapeutic segments.

Aarti Pharmalabs has an operating revenue of Rs. 1,967.98 Cr. on a trailing 12-month basis. An annual revenue de-growth of -5% needs improvement, Pre-tax margin of 16% is great, ROE of 12% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 84 which is a GOOD score indicating consistency in earnings, a RS Rating of 34 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C which is evident from recent supply seen, Group Rank of 56 indicates it belongs to a fair industry group of Medical-Ethical Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Aarti Pharmalabs Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-28 Quarterly Results
2024-08-05 Quarterly Results
2024-05-13 Audited Results & Final Dividend
2024-02-07 Quarterly Results & Interim Dividend
2023-11-07 Quarterly Results
Date Purpose Remarks
2024-07-31 FINAL Rs.1.00 per share(20%)Final Dividend
2024-02-19 INTERIM Rs.2.00 per share(40%)Interim Dividend

Aarti Pharmalabs F&O

Aarti Pharmalabs Shareholding Pattern

46.1%
4.93%
6.09%
7.38%
0%
29.45%
6.05%

About Aarti Pharmalabs

  • NSE Symbol
  • AARTIPHARM
  • BSE Symbol
  • 543748
  • Managing Director
  • Mr. Narendra J Salvi
  • ISIN
  • INE0LRU01027

Similar Stocks to Aarti Pharmalabs

Aarti Pharmalabs FAQs

Aarti Pharmalabs share price is ₹570 As on 21 December, 2024 | 17:55

The Market Cap of Aarti Pharmalabs is ₹5174.3 Cr As on 21 December, 2024 | 17:55

The P/E ratio of Aarti Pharmalabs is 22.7 As on 21 December, 2024 | 17:55

The PB ratio of Aarti Pharmalabs is 2.9 As on 21 December, 2024 | 17:55

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23